• Home
    • Leucémie myéloïde chronique
    • Leucemia Mieloide Crónica
  • CML Experts
    • Team of experts on CML who developed imatinib >
      • Dr. Elisabeth Buchdunger
      • Dr. Brian Druker
      • Dr. John Goldman
      • Dr. Carlo Gambacorti-Passerini
      • Dr. Nora C. Heisterkamp
      • Dr. David Hungerford
      • Dr. Nicholas Lydon
      • Dr. Alex Matter
      • Dr. Felix Mitelman
      • Dr. Peter C. Nowell
      • Dr. Moshe Talpaz
      • Dr. Janet D. Rowley
      • Dr. Charles Sawyers
      • Dr. Jürg Zimmermann
      • Dr. Owen Witte
    • Experts involved in developing dasatinib >
      • Dr. Jagabandhu Das
    • Experts involved in developing nilotinib
    • CML experts in America >
      • CML experts in Canada >
        • How to get the CMLer's password?
        • Dr. Sarit Assouline
        • Dr. Lambert Busque
        • Dr. Robert Delage
        • Dr. Connies Eaves
        • Dr. Josée Hébert
        • Dr. Marc Lalancette
        • Dr. Luigina Mollica
        • Dr. Dennis Kim
        • Dr. Pierre Laneuville
        • Dr. Pierre Laneuville (v. fr.)
        • Dr. Conrad Vincent Fernandez
        • Dr. Isabelle Bence-Bruckler
        • Dr. Jeffrey H Lipton
        • Dr. Mark Hnatiuk
      • CML experts in US >
        • How to get the CMLer's password?
        • Carolyn Blasdel, RN , FNP-BC, OCN
        • Rey Garcia, RN, BSN
        • PATRICIA JAKEL, RN, MN, AOCN
        • Dr. Charles Schiffer
        • Dr. B. Douglas Smith
        • Dr. Ravi Bhatia
        • Dr. Jorge E. Cortes
        • Dr. Javier Pinilla-Ibarz
        • Dr. Catriona Jamieson
        • Dr. Arul Chinnaiyan
        • Dr. Michael Deininger
        • Dr. James D. Griffin
        • Dr. Franziska Michor
        • Dr. Frank Giles
        • Dr. Gabriella Hobbs
        • Dr. Ehab Atallah
        • Dr. Elias J. Jabbour
        • Dr. Hagop Kantarjian
        • Dr. Harry P. Erba
        • Dr. Richard A. Larson
        • Dr. Alison Loren
        • Dr. Michael Mauro
        • Dr. Matt Kalaycio
        • Dr. Stephen D. Nimer
        • Dr. Ruben A. Mesa
        • Dr. Susan M. O'Brien
        • Dr. Jerald P. Radich
        • Dr. Ellen K. Ritchie
        • Dr. Karen Seiter
        • Dr. Kendra Sweet
        • Dr. Michael Savona
        • Dr. Neil Shah
        • Dr. Richard T Silver
        • Dr. Richard Stone
        • Dr. Raoul Tibes
        • Dr. Ronald L. Paquette
        • Dr. Sangmin Lee
        • Dr. Srinivas K. Tantravahi
        • Dr. Bin Zhang
      • CML experts in South America >
        • Dr. Michele Bianchini
        • Dra Beatriz Moiraghi
        • Dra. Carla Boquimpani
        • Dr Carolina Pavlovsky
    • CML Experts in Europe >
      • CML Expert in Belgium >
        • Pr Gregor Verhoef
      • CML expert in France >
        • Comment obtenir le mot de passe?
        • Dr. François-Xavier Mahon
        • Dr Aude Charbonnier
        • Dr. Agnès Guerci Bresler
        • Dr Pascale Cony-Makhoul
        • Dr. Delphine Rea
        • Dr. Gabriel Etienne
        • Dr. Lawrence Legros
        • Dr. Marie-Joëlle Mozziconacci
        • Pr. Mauricette Michallet
        • Dr. François Guilhot
        • Dr. ​Emilie Cayssial
        • Dr Françoise Huguet
        • Dr. Stéphane Prost
        • Dr. Philippe Rousselot
        • Dr. Eliane Gluckman
        • Dr. Franck-Emmanuel Nicolini
      • CML expert in Italy >
        • Dr. Carlo Gambacorti-Passerini
        • Dr. Chiara Elena
        • Dr. Gianantonio Rosti
        • Dr. Massimo Breccia
        • Dr. Michele Baccarani
        • Dr. Giuseppe Saglio
      • CML expert in UK >
        • Dr. Jane Apperley
        • Dr. Richard Clark
        • Dr. Stephen O'Brien
        • Dr. Georgios Nteliopoulos
        • Dr. Adam Mead
        • Dr. Tessa L Holyoake
      • CML expert in Germany >
        • Dr. Andreas Hochhaus
        • Professor Jörg Hasford
        • Professor Oliver Hantschel​
        • Dr Susanne Saussele
        • Dr. Martin Müller
      • CML expert in Portugal >
        • Dr. Antônio Medina de Almeida
      • CML expert in Spain >
        • Dr. Juan Luis Steegmann
      • CML expert in Netherlands >
        • Dr. Jeroen J.W.M. Janssen
      • CML expert in Sweden >
        • Dr. Johan Richter
      • CML expert in Czech Republic >
        • Dr. Hana Klamova
    • CML experts in Asia >
      • Dr. Annuar Rapaee
      • Dr. Charles Chuah
      • Dr. Goh Yeow Tee
      • Dr. Pankaj Malhotra
      • Dr. Uday Yanamandra
      • Dr. Hemant Malhotra
      • Dr. Kim Dong-Wook
    • CML experts in Africa >
      • Dr. Asmaa Quessar
      • Dr. Anthony Oyekunle
    • CML experts in Australia >
      • Dr. Ilaria Pagani
      • Dr. Susan Branford
      • Pr Tim Hughes
      • Dr. David T. Yeung
      • Dr. Liu Lu
      • Dr. Naranie Shanmuganathan
      • Dr. Anthony P Schwarer
  • Medical Concepts
    • Introduction to CML >
      • Precision medicine in chronic myeloid leukemia
      • Philadelphia chromosome
      • BCR-ABL Transcripts
      • Sokal, Hasford, and EUTOS scores
    • General concepts >
      • Blood
      • Bone Marrow
      • DNA
      • Stem Cells
      • Immune System >
        • Natural killer cell - NK
        • T Cells
      • Blood-Brain Barrier
    • Clinical Trials
    • Treatment response in CML
    • Resistance to treatment in CML >
      • Molecular monitoring in CML >
        • Polymerase Chain Reaction (PCR)
        • Dr. Kary Bank Mullis
      • Non-adherence of CML patients
      • Sensitive detection of BCR-ABL1 mutations
      • JAK2 Gene
    • Donor lymphocyte infusion (DLI)
    • Interferon regulatory factor 8 (IRF8)
    • Myeloproliferative disorders (MPD) >
      • Introduction to CML
      • Essential Thrombocythemia (ET)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
    • Types of leukemia >
      • Atypical chronic myeloid leukemia
  • Medication
    • How to get the CMLer's password?
    • Hydroxyurea
    • Interferon Alpha
    • Gleevec (Imatinib) >
      • Generic Imatinib
    • Tasigna (Nilotinib) >
      • Generic nilotinib
    • Sprycel (Dasatinib) >
      • Generic Dasatinib
    • Bosulif (Bosutinib)
    • Iclusig (Ponatinib)
    • Supect (Radotinib)
    • Scemblix (Asciminib)
    • Synribo (Omacetaxine )
    • HQP1351 (Olverembatinib)
    • Jakafi (Ruxolitinib)
    • K0706 (Vodobatinib)
    • Flumatinib
    • (Bafetinib)
    • Danusertib
    • DCC-2036 (Rebastinib)
    • BGB324
    • PF-114
    • NEV-801
    • ELVN-001
    • BP1001
    • S116836
    • Vidaza (Azacitidine)
  • Managing side effects
    • List of side effets >
      • How to get the CMLer's password?
      • Acid Uric - Gout
      • Bone Pain
      • Depression
      • Eyes
      • Ear
      • Fatigue
      • Fluid Retention
      • Gastrointestinal system
      • Hair
      • Heart
      • Hepatotoxicity
      • Kidney
      • Muscle cramping
      • Peripheral Neuropathy in CML
      • Peripheral arterial disease in CML
      • Pleural effusion
      • Pulmonary arterial hypertension
      • Thyroid dysfunction
      • Skin
      • Weight gain
    • CML and Nutrition
    • Food and Drug Interactions
    • Living with CML and diabetes
    • CML and comorbidities
    • Psycho-Oncology
    • Complementary and Alternative Medicine >
      • Art Therapy >
        • Art Therapist
        • CMLer's portofolio
      • Hypnotherapy
      • Music therapy >
        • YouTube creation by CMLer's family
        • Relaxing Music for Stress Relief. Calm Music for Meditation, Sleep, Healing Therapy, Spa
        • Debussy – Relaxing music - Clair de lune et autres...
        • Delicate music for the soul and LIFE, and birdsong soothes the nervous system.
        • Adagio for Strings (Samuel Barber)
        • Amélie Soundtrack ♥ Comptine d'Un Autre Été
        • The song "Disenchanted'
      • Yoga
      • Physical Activity
      • Zootherapy
  • Patient Testimonials
    • 30 years and plus survivors >
      • How to get the CMLer's password?
      • Mark Popadick
      • Mary Sullivan
      • Dr. Robert Patenaude -E
      • Skip Duffe
      • Sister Shirley Vaughn
    • 20 years and plus survivors >
      • How to get the CMLer's password?
      • Doug Jenson
      • Giora Sharf
      • Joannie Clements
      • Mel Mann
      • Kevin Williams
      • Rich Jones
      • Tanja Fajon
      • Tamera Simonson
      • Virginia Garner
    • 10 years and plus survivors >
      • How to get the CMLer's password?
      • Dan Sloan
      • Drew Johnston
      • Erin Zammett Ruddy
      • Erin Havel (Author)
      • Gary Gonzales
      • Jan Geissler
      • Jean McGlynn
      • Jo'story
      • Kayla Naton (Pregnancy)
      • Leanne
      • Mary Jane Bertram
      • Pat Elliott
      • Rob Shick
      • Tegan Kubler
      • Tom Cleaver
      • Sohag
    • New CMLers >
      • How to get the CMLer's password?
      • Skye Davidson
      • Amanda Steffy
      • Abbi Evans
      • Alyssa
      • Austin Granatowicz
      • Brown Dudley
      • Nigel
      • Katie
      • Kris
      • Ron Robbecke
    • Celebrities with CML >
      • How to get the CMLer's password?
      • Alexa Score
      • Brian Boyle
      • Carlos Carrasco
      • Charlie Schlatter
      • Doris Muramatsu
      • Dr. Richard Rockefeller
      • Greg Lemond
      • Kareem Abdul-Jabar
      • Kelvin Alston
      • Jason Blake
      • Laura Boyd
      • Lee Zeldin
      • Rick Upchurch
      • Roman Reigns
      • Ryan O'Neal
      • Tim Holcomb
    • Suzan Mc Namara and the petition
    • Bud Romine - the first patient
    • Other testimonials
    • Blogs >
      • How to get the password?
      • Living with CML
      • Michelle D's Blog
      • Jon's Blog
      • Trey's Blog
      • Blogs not recently updated >
        • Access CML Drugs
        • CMKID's blog – Dislodging the bullet - 2012
        • CML Recovery - Stopping KTI -2011
        • Hans's Blog -2012
        • Elizabeth's Blog - my leukemia - 2013journey
        • Elizabeth's Blog - Heart of the rose -2011
        • Joe's Blog - 2012
        • Josh's Blog - 2014
        • Mannan's Blog -2014
        • Ian's Blog -2014
        • Matt's Blog - 2012
        • Matthew's Blog - 2014
        • Michelle's Blog -2012
        • Nayree's Blog -2011
        • Rob's Blog - 2011
  • Global News on CML
    • English - Latest CML News >
      • News -Archives 2021-2020
      • News -Archives 2019-2018
      • News - Archives 2017-2016
      • News Archives - 2015-2014
      • News-Archives -2013-2012
      • News - Archives 2011-2001
    • French (Français) - Dernières nouvelles
    • Spanish (Español)-Ultimas noticias
  • Links to other sites, forums and Facebook
    • Sites (English and other languages)
    • Forums (English and other languages)
    • CML on Facebook
    • CML on Twitter
    • Audio Podcast
  • Various topics
    • How to get the CMLer's password?
    • CML patients and the coronavirus
    • You’ve just been diagnosed
    • History of CML
    • CML causes
    • Pronostic, life expectancy, quality of life, ..... in chronic myeloid leukemia
    • Increased Risk of Secondary Cancers with CML
    • Vaccination of CMLers
    • CML Blast Crisis treatment
    • Bone marrow transplant
    • Stem cells from umbilical cord blood
    • Children with CML
    • CML and pregnancy
    • Mutation T315I
    • Elderly patients with CML
    • Sports with CML
    • CML Awareness Day >
      • Journée mondiale de sensibilisation à la leucémie myéloïde chronique
    • The movie "Dying to Survive"
    • The movie 'The Blue Butterfly"
  • Cure possible for CML?
    • How to get the CMLer's password?
    • Hematopoietic stem cell transplantation using single UM171-expanded cord blood >
      • Greffe de cellules souches de cordon ombilical amplifiées par la molécule UM171
    • Combination of tyrosine kinase inhibitor with other medication >
      • Combinaison of hydroxychloroquine with tyrosine kinase inhibitor
      • Combination of ruxolitinib with tyrosine kinase inhibitor
      • Combination of miristen with tyrosine kinase inhibitor
      • Combination of pioglitazone with tyrosine kinase inhibitor
      • Combination of Inecalcitol with tyrosine kinase inhibitor
      • Combination of dasatinib plus Nivolumab
      • Combination of Pembrolizumab with tyrosine kinase inhibitor
      • Combination of interferon with tyrosine kinase inhibitor
      • Combination of Venetoclax with tyrosine kinase inhibitor
    • Inhibitory effect of c-Myc on p53-induced apoptosis in leukemia cells
    • Inhibition of the protein Ezh2 can cure CML?
    • Inhibition of STAT5 in conjunction with standard TKI therapy
    • PROTAC-mediated Targeted Protein Degradation
    • CML vaccine
    • Can immunotherapy cure leukemia?
    • Could fasting cure chronic myeloid leukemia
    • Chimeric Antigen Receptor T-Cell Therapy
    • Can genetic sequencing help to cure leukemia?
    • Can the new drug CX-5461 cure leukemia?
    • CRISPR-Cas9 gene-editing technique
    • Presence of bcr abl fusion transcripts in healthy individua
    • Math could help cure leukemia
    • Natural Medicine >
      • Possible cure for CML in Fish Oil
      • Betel leaf may help fight CML
      • Feverfew extract (parthenolide)
      • Can dandelions kill cancer?
      • Can curcumin cure leukemia?
  • Treatment-Free remission(TFR)
    • The French trial called STIM (Stop Imatinib)
    • De-escalation of treatment
    • Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients
  • Educational videos (all languages)
    • Educational videos in English
    • Vidéos pédagogiques en français sur la LMC
    • Videos instructivos en español
  • Educational events
  • CML Tool Box (all languages)
    • English tool box
    • French tool box
    • Spanish tool box
    • Know your CML
    • My CML
  • CML Glossaries
  • Moral Support
    • Where to get help and support
    • Family support
    • Dances at the Cancer Research Centre
    • I Had Cancer: You are not alone
    • I’m A Doctor With Chronic Illness. Here Are 12 Things I Wish People Knew
    • 23 Nice Things You Can Do for Someone With Cancer
    • Stronger
    • The march toward healing
    • Be happy
  • Congresses, conferences, meetings ASH, ASCO, EHA ...
    • ASCO - American Society of Clinical Oncology >
      • ASCO 2022 - Chicago
      • ASCO 2021 - Chicago
      • ASCO 2020 - Chicago
      • ASCO 2019 - Chicago
      • ASCO 2018 - Chicago
      • ASCO 2017 - Chicago
      • ASCO 2016 - Chicago
      • ASCO 2015 - Chicago
      • ASCO 2014 - Chicago
      • ASCO 2013 - Chicago
      • ASCO 2012 - Chicago
      • ASCO 2011 - Chicago
      • ASCO 2010 - Chicago
    • ASH - American Society of Hematology >
      • ASH 2022 - Virtual and New-Orleans
      • ASH 2021 - Virtual
      • ASH 2020 - Virtual
      • ASH 2019- Orlando
      • ASH 2018 - San Diego
      • ASH 2017 - Atlanta
      • ASH 2016 - San Diego
      • ASH 2015 - Orlando
      • ASH 2014 - San Francisco
      • ASH 2013 - New Orleans
      • ASH 2012 - Atlanta
      • ASH 2011 - San Diego
      • ASH 2010 - Orlando
      • ASH 2009 - New Orleans
    • BTG - Bridging the Gap >
      • BTG2019 - Fuzhou - China
      • BTG2018 - Seoul, Korea (South)
      • BTG 2011 - Singapore (Singapore)
    • CML & MPDs - UK National Meetings
    • CML Horizons >
      • CML Horizon 2019 - Lisbon - Portugal
      • CML Horizon 2018 -Warsaw (Pologna)
      • CML Horizon 2017- Frankfurt (Germany)
      • CML Horizon 2016 - Ljubljana (Slovenia)
      • CML Horizons 2015 - (Barcelona, Spain)
      • CML Horizons 2014 - ( Belgrade, Serbia)
      • CML Horizons 2013 - (Prague - Czech Republic)
      • CML Horizons 2012 - (Munich, Germany)
      • CML Horizons 2011 - (Amsterdam - The Netherlands)
    • EHA - European Hematology Association >
      • EHA 2022 - Hybrid Congress - Vienna
      • EHA 2021 -VIRTUAL
      • EHA 2020 - Frankfurt,Germany(
      • EHA 2019 - Amsterdam (Netherlands)
      • EHA 2018 - Stockholm(Sweden)
      • EHA 2017 - Madrid (Spain)
      • EHA2016-Copenhagen,(Denmark)
      • EHA 2015 - Vienne (Austria)
      • EHA 2014 - Milan (Italy)
      • EHA 2013 - Stockholm (Sweden)
      • EHA 2012 - Amsterdam (The Netherlands)
      • EHA 2011 - London (England)
      • EHA 2010 - Cascais (Portugal)
      • EHA 2009 - Berlin (Germany)
      • EHA 2008 - Copenhague (Danemark)
    • ESH - European School of Haematology >
      • ESH 2022 - Mandelieu-La Napoule, France
      • ESH 2021 - Virtual
      • ESH 2020 -Virtual
      • ESH 2019 - Bordeaux - France
      • ESH 2016 - Houston - USA
      • ESH 2015 - Estoril - Portugal
      • ESH 2014 - Philadelphia
  • Professionnel help and literature
    • Dr. Siddhartha Mukherjee
  • Patient Rights
  • New technological advances
  • International publications
    • Publications from Africa
    • Publications from America
    • Publications from Australia
    • Publications from Asia
    • Publications from Europe
  • Specialist Journals in Hematology/Oncology
  • Survey
    • Sondage-LMC
  • Private group registration
    • Membership registration - CMLeukemia private group
  • Awards & Recognition
  • Foundations
    • Leukemia Foundations >
      • American Cancer Society
    • Hospital Foundations
  • DONATE
    • Faire un don
    • DONAR
  • About us
    • Our mission
    • Contact us >
      • Nous contacter >
        • Contácte nos.
Chronic Myeloid Leukemia

Combination of pioglitazone with tyrosine kinase inhibitor    - CML - Chronic myeloid leukemia

Important notice: You must inform your CML doctor or a qualified doctor before using this drug. The material presented here is for information purposes only;  it is not a substitute for your physician’s guidance and care. The side-effects of pioglitazone would also to be taken into account if this treatment were to be offered in routine care.  

" ​Philippe Leboulch, M.D., a professor of medicine and cell biology at the University of Paris, and colleagues temporarily administered pioglitazone in addition to imatinib to three patients with chronic myeloid leukemia.

​
The researchers note that glitazones are agonists of peroxisome proliferator-activated receptor-γ (PPARγ). They report that activation of PPARγ by the glitazones reduces expression of STAT5 and the downstream targets HIF2α5 and CITED26, guardians of the quiescence and stemness of CML leukemia stem cells.
"When pioglitazone was given temporarily to three chronic myeloid leukemia patients in chronic residual disease in spite of continuous treatment with imatinib, all of them achieved sustained complete molecular response, up to 4.7 years after withdrawal of pioglitazone," the authors write. "This suggests that clinically relevant cancer eradication may become a generally attainable goal by combination therapy that erodes the cancer stem cell pool."

Extract of     Addition of Glitazone to Chemo May Help Treat CML by Pratice Update



"Here we show that the residual CML LSC pool can be gradually purged by the glitazones, antidiabetic drugs that are agonists of peroxisome proliferator-activated receptor-γ (PPARγ). We found that activation of PPARγ by the glitazones decreases expression of STAT5 and its downstream targets HIF2α5 and CITED26, which are key guardians of the quiescence and stemness of CML LSCs.

When pioglitazone was given temporarily to three CML patients in chronic residual disease in spite of continuous treatment with imatinib, all of them achieved sustained CMR, up to 4.7 years after withdrawal of pioglitazone. This suggests that clinically relevant cancer eradication may become a generally attainable goal by combination therapy that erodes the cancer stem cell pool."


Extract of    Prost S, Relouzat F, Spentchian M, et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists. Nature. 2015. doi:10.1038/nature15248


More about pioglitazone ​with wikipedia
​

VIDEOS

What Are the Side Effects of Actos (Pioglitazone)?

Pioglitazone

Diabetes & prediabetes:: Metformin vs Pioglitazone: side effects vs benefits
April 8, 2017, Ford Brewer MD MPH

Pioglitazone to Prevent Vascular Events - IRIS Study Reviewed
May 12, 2016, iForumRx

Common Diabetes Rx May Be Safer Than Previously Thought
July 21, 2015, dailyRx


​

CLINICAL TRIALS


Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW) (ACTIW)     
CML ACTIM  (European Leukemia Trial Registry)

Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia (SESPI)

Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia

Pioglitazone Hydrochloride and Tyrosine Kinase Inhibitor in Treating Patients with Relapsed Chronic Myeloid Leukemia

Second STOP After Pioglitazone Priming in CML Patients (PIO2STOP)

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients.

Cohort Study of Pioglitazone and Bladder Cancer in Patients With Type II Diabètes

​
Efficacy of Pioglitazone and Insulin in Treating Subjects With Type 2 Diabetes Mellitus and Renal Failure


.
ARTICLES

Five-Year Follow-up of the Phase I/II Discontinuation Trial of Imatinib after Pioglitazone (EDI-PIO) in Chronic Myeloid Leukemia Patients in Deep Molecular Response
​December 12, 2022, ASH 2022  

Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial (EDI‐PIO) in chronic myeloid leukemia with deep molecular response
August 30, 2020,  American Journal of Hematology

Pioglitazone Did Not Affect PPAR-Γ, STAT5, HIF2α and CITED2 Gene Expression in Chronic Myeloid Leukemia Patients with Deep Molecular Response
December 7, 2019, ASH 2019    

Prescribing Trend of Pioglitazone After Safety Warning Release in Korea
November 19, 2019, AJMC
​
Adding Oral Pioglitazone to Standard Induction Chemotherapy of Acute Myeloid Leukemia: A Randomized Clinical Trial
January 2019, Clinical Lymphoma, Myeloma & Leukemia

Abstract 1835: PPARγ agonist in combination with bcr/abl tyrosine kinase inhibitors in patients of chronic myeloid leukemia in chronic phase with suboptimal molecular response
July 2018, Cancer Research

In emerging area of ‘diabetic lung disease,’ pioglitazone may play preventive role
July 16, 2018, Healio

Pilot Study of Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia with Deep Molecular Response (EDI-PIO) – Evaluation of Pioglitazone in Treatment-Free Remission
December 2017, ASH2017

Pioglitazone Prevents Stroke in Patients with a Recent TIA or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial
October 30, 2017, Circulation
 
Pioglitazone And Metformin (Precautions)   WARNING
March 1, 2017, Mayo Clinic

Pioglitazone Plus Imatinib Leads to Molecular Response in Patients With Chronic-Phase Chronic Myeloid Leukemia
January 25, 2017, ASH clinicals news

Adding Pioglitazone Could Improve Molecular Response in CML Patients
Janvier 6, 2017, Cancer Network

Adding Pioglitazone to Imatinib May Improve Response Rate in CML
January  4, 2017,  Cancer Therapy Advisor

Pioglitazone could induce remission in major depression: a meta-analysis
December 2016, Altmetric

Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study                                             ********* must be seen ******
December 27, 2016, Cancer
​
PPAR GAMMA Agonist in combination with BCR/ABL TKI in patients of CML-CP with suboptimal molecular response
December 20, 2016, Annals of Oncology

Pioglitazone-induced congestive heart failure and pulmonary edema in a patient with preserved ejection fraction
March 2016,  Journal of Phamacology and Pharmaco therapeutics   ​WARNING
​
An Antidiabetic Medication For Curing Chronic Myeloid Leukemia
January 25, 2016, Richard Béliveau

Pioglitazone, Other TZDs May Add Benefit to TKI Therapy in CML
January 11, 2016, Cancer Network

PPARγ ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells
January 8, 2016, Nature

Teaching an Old Dog New Tricks: Eradication of Leukemia Stem Cells
December 2015, ASH Publications

PPARγ: Welcoming the New Kid on the CML Stem Cell Block
October 12, 2015,  Cancer Cell

Pioglitazone purges quiescent CML stem cells
September 17, 2015, Nature


Adding pioglitazone to imatinib may improve treatment of chronic myeloid leukemia
September 9, 2015, Oncology Nurse Advisor

Adding Glitazone to Chemotherapy May Help Treat Chronic Myeloid Leukemia
September 3, 2015, Cancer Therapy Advisor

Diabetes drug may help in leukaemia
September 3, 2015, BBC News

Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists
September 2, 2015, Journal Nature

Could Common Diabetes Drugs Help Fight Leukemia?
September 2, 2015, WebMD

Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy
March 2014, Heamatologica

Targeting STAT5 Expression Resulted in Molecular Response Improvement in Patients with Chronic Phase CML Treated with Imatinib
2012,  Journal Blood


The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study            WARNING
​April 18, 2012, thebmj
​

Pioglitazone Inhibits Platelet Function and Potentiates the Effects of Aspirin       WARNING
​​November 18, 2011, Journal Blood

Diabetes drug pioglitazone (Actos): risk of fracture  WARNING
Septembre 27, 2007, NCBI

Pioglitazone inhibits the growth of human leukemia cell lines and primary leukemia cells while sparing normal hematopoietic stem cells
August  29, 2006, PubMed


Pioglitazone Ameliorates Insulin Resistance and Diabetes by Both Adiponectin-dependent and -independent Pathways
 March 31, 2006, Journal of Biological Chemistry
​
Treating type 2 diabetes in renal insufficiency: the role of pioglitazone
October 2003, PubMed

                        
                                      
                                                See also Dr. Philippe Rousselot  
                                   See also Dr. Stéphane Prost  


                                  
See also Living with CML and diabètes
           See also  Inhibition of STAT5 in conjunction with standard TKI therapy  

                                        Return to Cure possible for  CML?
                        
Our disclaimer       Notre avis de non-responsabilité     Nuestro descargo de responsabilidad
  Privacy Policy              Politique de confidentialité                  Politica de Confidencialidad   
                    
Copyright © 2010-2023 CMLeukemia.com
Protected by Copyscape     DMCA.com Protection Status